Skip to content
Screener

BioLife Solutions BLFS Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Azenta logo
AzentaAZTA
$1M
Revvity logo
RevvityRVTY
$1M0.0%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$20M0.0%
Paysign logo
PaysignPAYS
$25M0.0%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$28.5M+21.5%
Gross profit$18.3M+20.0%
Operating income$1.7M+111%
Net income$45.1M+385%
EPS (diluted)$0.91+376%

Balance sheet

See full
Cash & equivalents$24.0M-24.8%
Total debt$15.7M-33.9%
Total equity$420.0M+21.0%
Total assets$447.5M+15.6%

Cash flow

See full
Operating cash flow$6.3M-13.8%
CapEx$1.0M-40.2%
Free cash flow$5.3M-5.7%

Valuation

See full
Market cap$1.69B+56.2%
Enterprise value$1.69B+56.6%
P/E54.5×
P/S16.5×+3.2×

Profitability

See full
Gross margin67.2%
Operating margin1.6%
Net margin-68.7%
FCF margin-15.9%+18.7pp

Returns & leverage

See full
Return on equity-14.5%-4.7pp
Debt / equity0.0×
Current ratio9.7×+5.3×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The source filing: BioLife Solutions’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:22 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054355
(In thousands, except per share and share data)June 30, 2026December 31, 2025
Total liabilities27,49133,996
Commitments and contingencies (Note 11)
Shareholders’ equity:
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.001 par value; 150,000,000 shares authorized, 48,889,090 and 48,198,928 shares issued and outstanding, respectively, as of June 30, 2026 and December 31, 20254948
Additional paid-in capital713,571711,404
Accumulated other comprehensive (loss) income, net of tax(211)132
Accumulated deficit(293,406)(339,696)

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is BioLife Solutions's preferred stock, shares authorized?
BioLife Solutions (BLFS) reported preferred stock, shares authorized of $1M in Q2 2026.
How has BioLife Solutions's preferred stock, shares authorized changed year-over-year?
BioLife Solutions's preferred stock, shares authorized decreased by 0.0% year-over-year, from $1M to $1M.
What is the long-term trend for BioLife Solutions's preferred stock, shares authorized?
Over 3 years (2022 to 2025), BioLife Solutions's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $1M to $1M.
What does preferred stock, shares authorized mean?
Preferred Stock, Shares Authorized

Ask your AI about BioLife Solutions's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude